Historique
Auteur E. D. COLLINS
Documents disponibles écrits par cet auteur (8)
Ajouter le résultat à votre sélection Affiner la recherche
E. D. COLLINS ; H. D. KLEBER ; R. A. WHITTINGTON ; HEITLER N. E. | 2005
Dans Journal of the American Medical Association (Vol.294, n°8, August 24/31, 2005) Article : PériodiqueContext: Rapid opioid detoxification with opioid antagonist induction using general anesthesia has emerged as an expensive, potentially dangerous, unproven approach to treat opioid dependence. Objective: To determine how anesthesia-assisted de[...]
M. HANEY ; E. W. GUNDERSON ; H. JIANG ; E. D. COLLINS ; R. W. FOLTIN | 2010
Dans Biological Psychiatry (Vol.67, n°1, January 2010) Article : PériodiqueBACKGROUND. Rates of relapse among cocaine-dependent patients are high, and new treatment approaches are needed. Clinical data demonstrate that a cocaine vaccine (TA-CD) produces selective anticocaine antibodies, yet the impact of these antibodi[...]
ENGLISH : Data from research with laboratory animals indicate that cocaine self-administration can be reduced by A-aminobutyric acid (GABA) agonists. Yet, the effectiveness of GABA agonists to decrease human cocaine self-administration has not[...]
B. FAVRAT ; J. BESSON ; M. M. MILLER ; E. D. COLLINS ; H. D. KLEBER ; R. A. WHITTINGTON ; CONTRERAS J. A. ; C. J. DE JONG ; P. G. O'CONNOR | 2006
Dans Journal of the American Medical Association (Vol.295, n°8, February 22, 2006) Article : PériodiqueDr Collins and colleagues studied anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction. The article and the accompanying editorial by Dr OConnor showed that detoxification is not in itself a [...]
S. D. COMER ; E. D. COLLINS ; M. W. FISCHMAN | 2002
Dans Journal of Pharmacology and Experimental Therapeutics (Vol.301, n°1, April 2002) Article : PériodiqueSeveral sources indicate that intravenously administered buprenorphine may have significant abuse liability in humans. The present study evaluated the reinforcing effects of intravenously administered buprenorphine (0, 2, and 8 mg) in detoxified[...]
S. D. COMER ; E. D. COLLINS | 2002
Dans Journal of Pharmacology and Experimental Therapeutics (Vol.303, n°2, November 2002) Article : PériodiqueBuprenorphine is a partial μ-opioid agonist and κ-opioid antagonist currently under development as a maintenance medication for heroin dependence. Because of concerns about illicit diversion of buprenorphine, a combination tablet containing bupr[...]
E. D. COLLINS ; T. HORTON ; K. REINKE ; L. AMASS ; E. V. NUNES | 2007
Dans Journal of Substance Abuse Treatment (Vol.32, n°2, March 2007) Article : PériodiqueFor opioid-dependent patients, the need for detoxification has been a barrier to entry into long-term residential treatment. This report describes a retrospective observational cohort study with the first 38 opioid-dependent patients entering Fi[...]
